EFFECT OF ZINC OXIDE NANOPARTICLES ON NEUROBLASTOMA SH-SY5Y CELLS

1Jinghui Zheng, 1Theresia Schnurr, 1,2Kriya Dunlap, 3Deben Das and 1,2Lawrence Duffy

1Department of Chemistry and Biochemistry, 
2Institute of Arctic Biology, 
3Department of Mechanical Engineering, 
University of Alaska Fairbanks, Fairbanks, AK 99775, USA

Received 2014-01-08; Revised 2014-05-07; Accepted 2014-07-04

ABSTRACT

The Arctic and sub-arctic regions are impacted by the growth of the global nanotechnology industry and the transport of chemicals to the North. New nanotechnology industries, such as neural prosthetics, are bringing nanomaterials in direct contact with neurons and glial cells. Nanomaterials have unique chemical and physical properties that may lead to toxicological effects by interfering with normal cellular metabolism. Zinc Oxide Nanoparticles (ZnO NPs) are now very common and widely used in daily life. Over the last decade there have been reports that ZnO NPs can have negative impacts on plants and simple organisms. However, there is a paucity of research on the effects and mechanisms by which ZnO NPs impact neuronal cells. This report investigates how ZnO NPs interact with the neuroblastoma cell line SH-SY5Y. Using transmission electron microscopy, we observed that the ZnO NPs form 36 nm particles, on average and increased the level of the cytokine VEGF in extracellular fluid. Moreover, ZnO NPs, in presence of TNF-α, decreased the level of extracellular VEGF when compared with TNF-α treatment alone. These findings suggest a basis for further studies on the interactions of ZnO NPs with signal transduction pathways and their impact on the release of cytokines. The importance of developing cellular model systems to evaluate the toxicity of nanomaterials before they are released to the marketplace will benefit both the ecosystem and human health.

Keywords: Nanomaterials, ZnO Sh-SY5Y Cells, VEGF

1. INTRODUCTION

Nanoparticles (NPs) are particles with a diameter typically smaller than 100 nanometers (nm) that differ from their bulk form (diameter >1000 nm) and usually have unique properties. Zinc oxide and carbon-coated titanium alloys are two examples of commonly used NPs (Yang et al., 2010). NPs are also used in the pharmaceutical field to develop substances for drug delivery (De Jong and Borm, 2008). This is especially true for the anticancer, anti-bacterial and anti-viral drug development industries. Although nanomaterials bring benefits, they also can have negative impacts on the ecosystem (Buzea et al., 2007). The NPs’ unique surface properties (i.e., the charge and the reactivity) can lead to biological effects such as inflammation and brain cancer. Since some NPs can pass the blood brain barrier based on their small size (De Jong and Borm, 2008), they will have access to neurons. Several toxicological studies support the contention that airborne NPs with diameters of less than 10 microns are correlated with inflammatory effects (Dobrovolskaia et al., 2008; Borm et al., 2006).

ZnO NPs are one of the common metal nano materials in current use. In the construction industry, ZnO NPs are used to coat wood, plastic or textiles to...
Cytokines are a group of proteins that play an important role in cell signaling in higher vertebrates. Upon cellular stimulation, cytokine levels increase in plasma after trauma or infection and are used as biomarkers by clinicians to monitor for inflammation (Hopkins et al., 2012; Kemp et al., 2005; Fava et al., 1994). Cytokines, such as Interlukin-1 (IL-1) and Tumor Necrosis Factor-α (TNF-α), are involved in the immune response to infection and are characterized as pro-inflammatory (Boyle, 2005). Production of the pro-inflammatory cytokines has been associated with tumor growth in neoplasms (Duffy et al., 2011) and the IL-1 family is important in both acute and chronic inflammation. IL-1 receptor binding induces the activation of transcription factors and the expression of genes that promote the production of other cytokines as well as growth factors, such as Vascular Endothelial Growth Factor (VEGF). VEGF is expressed by rodent and human tumor cells (Kemp et al., 2005; Roskoski, 2007; Duffy et al., 2011). VEGF expression has been found in activated macrophages (Fava et al., 1994), keratinocytes (Brown et al., 1992b), renal glomerular visceral epithelium and mesangial cells (Brown et al., 1992a; Iijima et al., 1993), hepatocytes (Monacci et al., 1993); smooth muscle cells (Ferrara et al., 1991), embryonic fibroblasts, bronchial, choroid plexus epithelia cells (Pertovaara et al., 1994; Breier et al., 1992; Cao et al., 1996) as well as neurons and glial cells (Storkebaum and Carmeliet, 2004). In vivo, VEGF can induce angiogenesis, a process that is associated with wound healing, embryonic development and the growth and metastasis of solid tumors, as well as an increase in microvascular permeability (Kemp et al., 2005). Based on all the factors listed above, VEGF is an important signaling molecule in inflammation and angiogenesis. Elevated levels of VEGF have been reported in synovial fluids of rheumatoid arthritis patients and in sera from cancer patients (Koch et al., 1994; Senger et al., 1993; Kondo et al., 1994). Based on this background, our goal was to develop a cell culture system to study the effect of ZnO nanoparticles on a neuronal neuroblastoma cell line which secretes VEGF. We asked two main questions: (1) Do ZnO NPs have a uniform and stable size in our cell culture system and (2) will ZnO NP exposure impact the release of VEGF by 5H-SY5Y cells?

2. MATERIALS AND METHODS

2.1. Human SH-SY5Y Cell Culture

Human SH-SY5Y neuroblastoma cells were grown from the frozen cells which were stored in liquid nitrogen, then thawed into 100 mm dishes (Falcon) containing: High-glucose DMEM (pH 7.4), 10% Fetal Bovine Serum (FBS), 3.7 g L⁻¹ sodium bicarbonate, 100 U mL⁻¹ of penicillin and streptomycin and 1% GlutaMax-1 (GM). Cultures were incubated in a humidified atmosphere with 5% CO₂ at 37°C. After one week of incubation, cells were detached using 0.5 mg mL⁻¹ trypsin (5 min and 37°C), collected by centrifugation (1,200 rpm) and plated into six-well plates. After a week of incubation in the six-well plates, the media was replaced with serum-free media for the assay. All experiments were carried out 24 h after depriving the neuron cultures of serum (Gustafson et al., 2012).

2.2. Light Microscopy of SH-SY5Y Cell

After one week’s growth in a six-well plate, neuroblastoma cells were observed under the Nikon Eclipse TE 2000U inverted microscope to assess the normal condition of the cells. Morphology changes after the treatments were noted. Normal morphology shows asymmetric cells with processes.

2.3. Transmission Electron Microscopy

Transmission Electron Microscopy (TEM, JEOL 1200) was used to detect the morphology characteristics of ZnO NPs. ZnO NPs were mixed with...
Propylene Glycol (PG) in a 1:9 PG ratio (10 µL of NPs and 90 µL PG) for a 10% final solution. 5 µL of prepared ZnO NPs solutions were pipetted on to the TEM grid and after 20s, were blotted off the SEM grid, then 5 µL of DI water was placed on the grid for 20 s and blotted from the grid. After repeating 3 times, the grid was dried overnight. The grid of ZnO NPs was examined after one day.

2.4. BCA Protein Assay

The BCA protein assay (Pierce) is commonly used to determine protein content in samples. It is a detergent compatible formulation based on bicinchoninic acid for the colorimetric detection and quantitation for total protein in the samples. The assay is based on the principle that Cu2+ is reduced to Cu1+ by protein in an alkaline medium which is called the biuret reaction. The reaction is detected with a highly-sensitive and selective colorimetric detection of the Cu1+ using a unique reagent containing bicinchoninic acid. The final color of the solution will be purple and depends on the concentration of proteins existing in samples. The colors can also appear in different shades. The purple color is caused by the chelation of two molecules of bicinchoninic with one Cu+.

2.5. VEGF Assay

The human VEGF ELISA assay (R and D System) was used for measurements of extra and intracellular VEGF from cultured human SH-SY5Y cells. By following published directions (R and D Systems), VEGF was detected in a colorimetric change plate. A Beckman-Coulter Multimode DTX 880 multi-plate reader detected the color change at an absorbance $\lambda = 450$ nm. After ZnO NPs and TNF-$\alpha$ treatments, the media was directly removed and utilized for the extracellular assay. The same remaining cells were rinsed with PBS. Cells were removed from the plates by scraping in ice-cold PBS, collected in Eppendorf tubes and sonicated for 5 sec.

2.6. Statistical Analysis

Data was analyzed using GraphPad Prism, statistical software (version 5.0) to evaluate significance between treatments. The difference between treatments was evaluated using an unpaired student’s t-test. Differences were considered significant at the $p<0.05$. All data are reported as means +or-SD.

3. RESULTS

3.1. Nanoparticle Shape

The size and shape of the ZnO NPs was observed using Transmission Electron Microscopy (TEM) at several magnifications. ZnO NPs tended to form aggregates in aqueous environments which is consistent with other ZnO NPs morphology studies (Fig. 1).

The ZnO NPs tended to form aggregates; but most individual particle’s size was smaller than 100 nm. Any effects of ZnO on the cell will be caused by its NPs form, not its larger Fine form in which particle diameters are between 100 and 1000 nm, or its Bulk form in which the particle diameter is larger than 1000 nm (Fig. 2).

The general morphology of ZnO NPs under the 500,000 magnification illustrates that ZnO NPs show elongated-type shapes: Oval; rectangular-elongated shape and round shape. The darker color of ZnO NPs in Fig. 2 indicates that ZnO NPs are overlapping. When magnification was expanded as seen in Fig. 3, the definition of these elongated ZnO NPs was more evident and the average size was estimated to be 36 nm. These particles exist within a narrow range size. The individual particle diameter is smaller than 100 nm. All these size characteristics, including the potential to aggregate over time, will impact their interactions with SH-SY5Y cells.

3.2. Cell Viability

The morphology of SH-SY5Y cells under 20X magnification after 24 h (in a serum-free media) demonstrates that the cells remained healthy. The cells maintained their projections and shape. Figure 4a illustrates the normal morphology of the cells in a serum-free media before treatment with ZnO NPs. High concentration of ZnO NPs after 24 h. of ZnO NPs treatment led to complete mortality of the cells. A series of concentrations and time-dependent experiments were then used to define conditions for observing impacts of ZnO NPs. Figure 4b shows the morphology of SH-SY5Y under 20X after 1 h. of 0.40 µL mL$^{-1}$ ZnO NPs treatment. The numbers of axon projection were reduced and some cells changed morphology to a rounded shape. After 4h, the morphology of SH-SY5Y of 5 µL mL$^{-1}$ ZnO NPs treatment showed that most cells lost their normal morphology and axon projections. There was almost complete disappearance of connectivity between cells (Fig. 4).
Fig. 1. ZnO NPs morphology under 100,000X

Fig. 2. ZnO NPs morphology under 300,000X
Fig. 3. ZnO NPs morphology under 500,000X

Fig. 4. (a) SH-SY5Y in serum free cell culture 4 (b) SH-SY5Y in ZnO NPs exposure (1h) (c) SH-SY5Y cell culture in ZnO NPs exposure (4 h)

3.3. VEGF Secretion

The level of VEGF extracellular secretion is dependent on incubation timing with TNF-α (Fig. 5). This is expected because the longer the exposure time the more the VEGF will be released into the culture. This data shows that VEGF release under the TNF-stimulation is a time-dependent behavior, the longer the exposure time, the more VEGF has been induced and secreted. These results are also consistent with previously reported results (Duffy et al., 2011), that a 30 min TNF-α incubation increases the extracellular VEGF level in culture media.
In **Fig. 6**, the 30 min TNF-α (2.5 µL mL\(^{-1}\)) treatment is shown as a baseline stimulation and positive control. The level of VEGF release after ZnO NPs (5 µL mL\(^{-1}\)) for 4h and followed by a 30 min TNF-α (2.5 µL mL\(^{-1}\)) treatment showed a significant reduction in VEGF release. This result indicates the ZnO NPs can interfere at the molecular level with the cellular cytokine signal transduction pathways. The effects of stressors, either cytokines or toxicants, can be additive, subtractive or synergistic. The inhibiting behavior in **Fig. 6** suggests that the effect of ZnO NPs on TNF-α stimulation appears to be subtractive.

![Fig. 5. VEGF extracellular releases after TNF-α treatments. Assessment of the VEGF extracellular releases after TNF-α treatments in SH-SY5Y cells. Cells were exposed to 2.5 µL mL\(^{-1}\) TNF-α for 30 min and 4 h. The methodology for assessment of the VEGF extracellular releases is described in Materials and Methods. Data are representative of three separate experiments. (p<0.05, t-test)](image1)

![Fig. 6. VEGF extracellular releases after combining TNF-α and ZnO NPs treatments. Cells were exposed to 2.5 µL mL\(^{-1}\) TNF-α for 30 min or 5 µL mL\(^{-1}\) ZnOPs for 4 h plus an additional 2.5 µL mL\(^{-1}\) TNF-α for 30 min. The methodology for assessment of the VEGF extracellular releases is described in Materials and Methods. Data are representative of three separate experiments. (p<0.05, t-test)](image2)
4. DISCUSSION

ZnO NPs have been used in many products. Previous studies (Bai et al., 2010) show that the aggregation effects can increase the toxicity of ZnO NPs. Transmission Electron Microscopy data results in this research demonstrate that ZnO NPs aggregate in solution and the average size of the particles is about 36 nm. Moreover, these particles have a heterogeneous shape and therefore they may potentially affect neuronal cells differently. However, there is no previously reported research on these neuronal cells. Some research reported that the smaller the size of nanoparticles, the more toxic their behavior (Kumari et al., 2011; Bruneau et al., 2013).

VEGF is a signal protein that is produced by numerous types of cells and can be induced by other cytokines. VEGF can stimulate new blood vessels and lymphatic vessels to grow under normal conditions. When VEGF is over-expressed, it can contribute to diseases, especially cancer. In advanced cancer studies, researchers create VEGF-receptors antagonists to block the VEGF production in tumor cells (Kerbel, 2000).

VEGF extracellular releases after combining ZnO NPs and TNF-α treatments. Assessment of the VEGF extracellular releases after combining ZnO NPs and TNF-α treatments in SH-SY5Y cells. Cells were exposed to 5 µL mL⁻¹ ZnO NPs for 4 h or 5 µL mL⁻¹ TNF-α for 30 min. The methodology for assessment of the VEGF extracellular releases is described in Materials and Methods. Data are representative of three separate experiments. (p>0.05, t-test)

![Fig. 7. VEGF extracellular releases after combining ZnO NPs and TNF-α treatments.](image)

After 4h treatment with ZnO NPs (5 µL mL⁻¹) alone or with TNF-α (2.5 µL mL⁻¹) treatment, there was no significant difference in extracellular VEGF (Fig. 7). This result also suggests that pretreatment of ZnO NPs inhibits the TNF-α induction of VEGF.

Our research reveals that after 4h incubations with ZnO NPs, the normal morphology of SH-SY5Y cells disappear. They lose their projections of axons and the interactions with nearby cells. The ELISA results show that ZnO NPs with a concentration of 5 µL mL⁻¹ increased the extracellular VEGF production after 4h incubation. In comparison, an exposure to TNF-α, with a concentration of 2.5 µL mL⁻¹, increased the extracellular VEGF production by about three-fold. In addition, we studied the combined effects of ZnO NPs and TNF-α to SH-SY5Y cells on VEGF secretion. The results show that the extracellular VEGF production is almost the same under ZnO NPs and ZnO NPs+TNF-α conditions (Fig. 7). The ZnO NPs+TNF-α treatment has less effect on extracellular VEGF production (160 pg mL⁻¹) than the TNF-α treatment alone (450 pg mL⁻¹). This result has two possible explanations (1) the ZnO NPs can inhibit the release of VEGF in the presence of TNF-α, which can be used in the development of a potential cancer drug or (2) the ZnO NPs killed the cells before they could release more VEGF into media. The second explanation needs further investigation because of a reduction in cellular protein content in ZnO NPs treated cells.

5. CONCLUSION

This research suggests that the ZnO NPs may interfere with the TNF-α regulating pathway (Fig. 8). This interference leads to reduction in the TNF-α-stimulated release of VEGF.
6. ACKNOWLEDGEMENT

We gratefully acknowledge helpful discussions with Mary van Muelken. This research was partially funded by the National Institute of Neurological Disease and Stroke 2U54-NS041069-10

7. REFERENCES


